Thank you for participating.
Thank you for your interest in participating in this important survey to help improve access to medications to Canada!
Please note that throughout this survey, ‘Nurtec’ refers to Nurtec ODT (rimegepant orally disintegrating tablets).
Your experience and opinions will help shape our submissions to CDA* and INESSS** for public reimbursement of Nurtec.
* Canadian Drug Agency (CDA)
** Institut national d’excellence en santé et en services sociaux (INESSS)
CDA and INESSS conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans across Canada (and INESSS for Quebec).
To help them make their recommendations, both institutions accept input from registered patient organizations, like Migraine Canada & Migraine Quebec.
If you live with migraine, please complete the survey by June 12 @ 11:59 ET, to give us time to prepare the submission by the deadline. Your input will be anonymous. This survey will take approximately 15 minutes to complete.
In this survey, you will be asked about:
· Your insights on what it means to live with chronic or episodic migraine
· Your experience with health care for migraine
· Your experience with available acute migraine treatments including first line treatments and medication overuse headache.
- Your experience with issues such as a cap on prescription and ineffectiveness.
· What you would consider is meaningful success (positive outcome)
· Your experience with NURTEC
We ask that you answer all the multiple-choice questions and share openly and honestly your personal testimonials in the open-ended questions.
Together, we hope to make migraine treatments accessible so everyone can find the most appropriate option available.
Thank you in advance for participating!
The Migraine Canada team
This survey is independently conducted by Migraine Canada and Migraine Quebec.